🔎 Trials Near Me

Home › NCT06100263

Breast Cancer Resiliency Through Exercise Program (B-REP)

Recruiting

Breast Cancer Resiliency Through Exercise Program (B-REP): Pilot Study

Who can join

Ages 18 and older · Women

Full eligibility criteria
Inclusion Criteria:

Women will be eligible if they meet the following criteria:

* self-identify as Black or African American or Afro-Latina/e;
* are ≥18 years old;
* have a confirmed diagnosis of breast cancer, Stage I to IIIA;
* have completed primary active treatment (i.e., surgery, chemotherapy, and radiation) within 5 years prior to study start where concomitant hormonal therapy is acceptable;
* are not meeting current cancer-specific resistance exercise guidelines of ≥ 2 times per week; and
* are able to speak and understand English.

Exclusion Criteria:

* metastatic disease;
* medical reason that precludes them from increasing current exercise levels;
* planned elective surgery during study period;
* pregnant or plans to become pregnant during the study period;
* plans to move out of United States during the study period; (the rationale for this exclusion is that it will be difficult to conduct the in-person assessments if a participant leaves the United States);
* current enrollment in another exercise trial; and/or
* inability to pass exercise pre-screening or receive physician consent to increase current physical activity levels.

About the study

The study will use a cross-sectional study design with a follow-up 2-arm randomized controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12), and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and waitlist control among 30 Black breast cancer survivors

What is being tested

Sponsor: University of Michigan Rogel Cancer Center · Participants: 75 · Started: May 28, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06100263

Locations in the U.S.

MichiganUniversity of Michigan, Ann Arbor

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.